Prestige Consumer Healthcare Inc. (PBH)
NYSE: PBHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 47.87 -0.02%
PBH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.27B
- P/E (TTM)
- 13.41
- Forward P/E
- 9.42
- EPS (TTM)
- $3.57
- Dividend yield
- None
- 52-week range
- 42.62 – 71.07
- Day range
- 46.76 – 47.94
- Volume / Avg
- 558.51K / 545.45K
- Beta
- —
- Shares outstanding
- 47.37M
- Next earnings
- Nov 5, 2026
52-week range
PBH stock today
On Oct 8, PBH ended the session at $47.87, adding $0.30 (0.63%), versus the S&P 500's 0.47% decline. At this level, PBH sits near the bottom of its 52-week range of $42.62 to $71.07: 32.6% below the high, set on Feb 24, 2026 and 12.3% above the low. PBH is down 22.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 24.3%.
Prestige Consumer Healthcare trades at 13.4x its trailing twelve-month earnings per share of $3.57. Its forward P/E of 9.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Prestige Consumer Healthcare's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Prestige Consumer Healthcare
Company profilePrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ronald M. Lombardi CPA
- Headquarters
- Tarrytown, NY
- Employees
- 890
- IPO year
- 2005
- Website
- prestigebrands.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$67.80+41.63%
- Strong buy 1
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.06
Prestige Consumer Healthcare peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHCBausch Health Companies Inc. | 6.04 | -1.79% | $2.26B | vs PBH |
| SLSSELLAS Life Sciences Group Inc. | 11.26 | -0.44% | $2.27B | vs PBH |
| IMNMImmunome Inc. | 19.31 | +1.13% | $2.28B | vs PBH |
| NRIXNurix Therapeutics Inc. | 22.21 | -2.29% | $2.30B | vs PBH |
| HRMYHarmony Biosciences Holdings Inc. | 39.60 | +0.66% | $2.31B | vs PBH |
| PHVSPharvaris N.V. | 31.12 | -1.77% | $2.18B | vs PBH |
| IRONDisc Medicine Inc. | 60.77 | -0.67% | $2.33B | vs PBH |
| AUPHAurinia Pharmaceuticals Inc | 16.22 | +1.31% | $2.16B | vs PBH |
Indexes, lists and sector
Prestige Consumer Healthcare stock FAQ
What is Prestige Consumer Healthcare's stock price today?
PBH last traded at $47.87 as of Oct 8, 4:00 PM EDT, up 0.63% on the day. Prices are delayed at least 15 minutes.
When is Prestige Consumer Healthcare's next earnings date?
Prestige Consumer Healthcare is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.06.
What is PBH's P/E ratio?
PBH trades at a trailing P/E ratio of 13.41 and a forward P/E of 9.42.
Who is Prestige Consumer Healthcare's CEO?
Mr. Ronald M. Lombardi CPA is the chief executive officer of Prestige Consumer Healthcare Inc., which has about 890 employees.
What is the PBH 52-week high?
The 52-week high for PBH is $71.07 and the 52-week low is $42.62. The stock is currently 32.6% below its high.